Evidence map›Paper›PMID 37140398›Full record

Trial reportMicrobiology spectrum2023

A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.

Taiga Miyazaki, Naoki Hosogaya, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Yoshihito Ozawa, Yuki Shiko, Yosuke Inaba and 29 more

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 15 institutions in 1 country.

Taiga MiyazakiDivision of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-0962-5758
Naoki HosogayaClinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
Yuri FukushigeClinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
Sachiko TakemoriClinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
Shinpei MorimotoClinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
Hiroshi YamamotoClinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
Makoto HoriDivision of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Yoshihito OzawaDivision of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Yuki ShikoDivision of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Yosuke InabaDivision of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Tomoya KurokawaDivision of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Hideki HanaokaDivision of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Shoya Iwanamiinterdisciplinary Biology Laboratory (iBLab), Division of Biological Sciences, Graduate School of Science, Nagoya University, Aichi, Japan.
Kwangsu Kiminterdisciplinary Biology Laboratory (iBLab), Division of Biological Sciences, Graduate School of Science, Nagoya University, Aichi, Japan.
Shingo Iwamiinterdisciplinary Biology Laboratory (iBLab), Division of Biological Sciences, Graduate School of Science, Nagoya University, Aichi, Japan.
Koichi WatashiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
Ken MiyazawaDepartment of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0001-9211-1020
Takashi UmeyamaDepartment of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan.
Satoshi YamagoeSection of Infectious Resource Coordination, Department of Research Resource, Center of Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Yoshitsugu MiyazakiDepartment of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0001-8942-0869
Takaji WakitaNational Institute of Infectious Diseases, Tokyo, Japan.
Makoto SumiyoshiDivision of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tatsuro HirayamaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.ORCID 0000-0001-8554-3482
Koichi IzumikawaInfection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Hitoshi KawasujiDepartment of Infectious Disease, Toyama University Hospital, Toyama, Japan.
Yoshihiro YamamotoDepartment of Infectious Disease, Toyama University Hospital, Toyama, Japan.
Norihito TarumotoDepartment of Infectious Disease and Infection Control, Saitama Medical University Hospital, Saitama, Japan.
Hiroshi IshiiDepartment of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan.
Hideaki OhnoDepartment of Infectious Disease and Infection Control, Saitama Medical Center, Saitama, Japan.
Kazuhiro YateraDepartment of Respiratory Medicine, Hospital of the University of Occupational and Environmental Health, Japan, Fukuoka, Japan.
Hiroshi KakeyaDepartment of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yoshiko KichikawaDivision of Respiratory Medicine, Mishuku Hospital, Tokyo, Japan.
Yasuyuki KatoDepartment of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba, Japan.
Tetsuya MatsumotoDepartment of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba, Japan.
Makoto SaitoDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-1667-9287
Hiroshi YotsuyanagiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shigeru KohnoNagasaki University, Nagasaki, Japan.
Nagasaki University Hospital · JPChiba University Hospital · JPNational Institute of Infectious Diseases · JPNagoya University · JPInternational University of Health and Welfare · JPToyama University Hospital · JPUniversity of Miyazaki · JPUniversity of Tokyo Hospital · JPFukuoka University · JPNagasaki University · JPNational Center for Global Health and Medicine · JPOsaka Metropolitan University · JPSaitama Medical University Hospital · JPSocial Insurance Saitama Chuo Hospital · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Indexed as

Anti-HIV AgentsCOVID-19AdultHumansNelfinavirSARS-CoV-2Time FactorsTreatment OutcomeAnti-HIV AgentsNelfinavirCOVID-19nelfinavirprotease inhibitorrandomized controlled trialSARS-CoV-2

Identifiers

PMID37140398
PMCPMC10269734
OpenAlexW4368358022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.